• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Imugene Announces $80 Million Placement

Like 0

By Kiryll Prakapenka, Tuesday, 13 September 2022

On Tuesday, cancer immunotherapy developer Imugene [ASX:IMU] announced an $80 million placement to fund its clinical pipeline.

On Tuesday, cancer immunotherapy developer Imugene [ASX:IMU] announced an $80 million placement to fund its clinical pipeline.

The placement represents a discount of 11.1% to the share price at closure on 9 September 2022.

IMU shares were largely flat on Tuesday but are trading 50% down year to date.

ASX:IMU imugene stock chart

www.tradingview.com

Imugene’s $80 million placement

Imugene has said both its current cash position and the funds raised via the placement would provide the financial foundation for its ‘deep pipeline of clinical programmes’ with R&D rebates expected to make a further impact.

IMU also hinted that future partnering and licensing opportunities could extend this financial situation to an even greater degree but did not reveal what these might entail or who they could involve.

The placement specifics:

  • A total of 400 million new shares to placement subscribers at a price of 20 cents per share
  • The issue price represents a discount of 11.1% to the last close on 9 September 2022 (22.5 cents), and a discount of 12% to the five-day VWAP for 9 September (22.7 cents)
  • New shares issued under the placement represent around 6.8% of existing ordinary shares
  • For every two new shares subscribed, Imugene intends to issue a free new option attached (a total of 200 million new options will be offered to placement subscribers under a placement options offer)
  • New options are priced at 33 cents and have a set expiration date of 31 March 2026

If fully exercised, options issued under the Placement will provide a further $66 million in funding for the company’s clinical pipeline.

Two ‘leading’ institutional investors have already subscribed to the placement.

Imugene’s Founder and Executive Chairman Paul Hopper commented on the offer:

‘This capital raising ensures a long runway for the existing programmes while also providing flexibility to add complementary assets should attractive opportunities present. The ability to introduce two high calibre institutional investors onto the share register following what has been a volatile period across biotechnology indices speaks to the quality of the Company’s unique clinical platforms. With minimal dilution to existing shareholders of only 6.8%, and with such a definitive statement of investment support for Imugene by two prominent funds, the Board believes we have a significant opportunity to maximise value for all Imugene shareholders.’

Imugene’s Managing Director and CEO Leslie Chong also offered the following thoughts:

‘We are pleased to strengthen the company’s balance sheet and give ourselves an unimpeded runway to progress the numerous clinical trials that we have ongoing. By having these multiple shots on goal well-funded gives them the best chance of success, which we expect will translate into shareholder value and improved patient outcomes.’

The EV heartbeat beats strong

Now, it’s not breaking news that countries worldwide are striving to decarbonise.

And EVs are a big part of that strategy.

The mass adoption of EVs is set to boost demand in battery metals like ASX favourite lithium.

But there are others in the race.

In fact, the lithium frenzy has our Money Morning team thinking about a smarter way to play…

With lithium’s ‘little brother’ the star playing piece.

Regards,

Kiryll Prakapenka,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Kiryll Prakapenka

Kiryll’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Australia ain’t the USA…and that’s great!
    By Callum Newman

    The outlook for Australia and the ASX are very different to the US and US shares. Here’s why…

  • The biggest infrastructure spending boom in history just kicked off
    By Nick Hubble

    Did governments screw up our gas supply? According to some sources in the industry, a rather similar thing happened to our electricity and water industry.

  • You Read it Here First: Great Asset Rotation Underway
    By James Cooper

    Media is swirling on the great asset transition taking place from the banks to the miners. But James Cooper made this prediction months ago in Mining Memo. Are you taking advantage?

Primary Sidebar

Latest Articles

  • Australia ain’t the USA…and that’s great!
  • The biggest infrastructure spending boom in history just kicked off
  • You Read it Here First: Great Asset Rotation Underway
  • The sector primed to fly into 2026
  • OpenAI and Microsoft Divorce?: Why this could be good for you

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988